Most Read Articles
Roshini Claire Anthony, 13 Aug 2018

A genotype-guided approach to warfarin dosing may result in fewer dose adjustments in Asian patients, according to a study from Singapore.

Rachel Soon, 05 Dec 2018

At the recent Malaysian Community Pharmacy Business Forum (MyCPBF), a discussion forum was held on the subject of “Transcending Primary Healthcare Services: The Future of Specialized Pharmacy Services and Pharmacy Specialization”.

19 Jul 2018
Nonsteroidal anti-inflammatory drugs (NSAIDs) appear to increase the risk of major bleeding, stroke or systemic embolism, and hospitalization among patients with atrial fibrillation (AF), suggest the results of the RE-LY* trial. Moreover, there is no difference in the safety and efficacy of dabigatran etexilate (DE) 150 and 110 mg twice daily relative to warfarin.
Rachel Soon, 01 Mar 2018

Over half of consumers who use herbal supplements still do not inform physicians of their practices in consultation, according to a local study.

Pitavastatin superior to other statins for preventing diabetes in AMI patients

08 Oct 2018

Moderate-intensity pitavastatin appears to lower the incidence rate of new-onset diabetes mellitus (NODM) in acute myocardial infarction (AMI) patients, a recent study reports.

Researchers enrolled 2,001 AMI patients without diabetes mellitus, of whom 1,267 received atorvastatin (mean age 64.4±12.5 years; 76.6 percent male), 960 received rosuvastatin (mean age 63.2±12.4 years; 76.1 percent male) and 255 were given pitavastatin (mean age 63.4±12.0 years; 72.2 percent male). The cumulative NODM incidence was evaluated across the different groups.

Kaplan-Meier curves showed that the 3-year cumulative incidence rate of NODM was significantly lower in the pitavastatin group than in the atorvastatin and rosuvastatin groups (3.0 percent vs 8.4 percent and 10.4 percent; p=0.001).

Multivariate Cox regression analysis further provided proof for this association, showing that the type of statin taken was an important prognostic factor for NODM. Those who received atorvastatin (hazard ratio [HR], 2.6; 95 percent CI, 1.163–5.879; p=0.0201) or rosuvastatin (HR, 3.9; 1.756–8.689; p=0.0008) were significantly more likely to develop NODM than those who were given pitavastatin.

Notably, atorvastatin was superior to rosuvastatin in terms of NODM prognosis (HR, 0.669; 0.456–0.982; p=0.0401).

Other significant risk factors included triglyceride (HR, 1.004; 1.003–1.006; p<0.0001) and glucose (HR, 1.006; 1.003-1.008; p<0.0001) levels.

“The present study is the first study that evaluated the effect of statin type on NODM incidence in patients with AMI and compared diabetogenic effect among different same intensity statin therapies,” said researchers.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Roshini Claire Anthony, 13 Aug 2018

A genotype-guided approach to warfarin dosing may result in fewer dose adjustments in Asian patients, according to a study from Singapore.

Rachel Soon, 05 Dec 2018

At the recent Malaysian Community Pharmacy Business Forum (MyCPBF), a discussion forum was held on the subject of “Transcending Primary Healthcare Services: The Future of Specialized Pharmacy Services and Pharmacy Specialization”.

19 Jul 2018
Nonsteroidal anti-inflammatory drugs (NSAIDs) appear to increase the risk of major bleeding, stroke or systemic embolism, and hospitalization among patients with atrial fibrillation (AF), suggest the results of the RE-LY* trial. Moreover, there is no difference in the safety and efficacy of dabigatran etexilate (DE) 150 and 110 mg twice daily relative to warfarin.
Rachel Soon, 01 Mar 2018

Over half of consumers who use herbal supplements still do not inform physicians of their practices in consultation, according to a local study.